Endpoints News 2. Dez. 2025 ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisition
Endpoints News 2. Dez. 2025 Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drug
Endpoints News 2. Dez. 2025 As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers
Endpoints News 2. Dez. 2025 Imvax shares Phase 2b data for glioblastoma treatment, plans to meet with FDA
Endpoints News 1. Dez. 2025 Janux’s prostate cancer immunotherapy’s response rate drops, according to new early-stage data
Endpoints News 1. Dez. 2025 Belite Bio aims for first approval of Stargardt disease treatment with Phase 3 success